We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 3,492

Washington Healthcare Update - Jul 2, 2018
  • McGuireWoods LLP
  • USA
  • July 2 2018

House GOP appropriators have again postponed consideration of their Labor-HHS-Education spending bill. The markup, which had been rescheduled for

Connecticut and Maine Become the Latest States to Adopt New Drug Pricing Transparency Laws
  • Arent Fox LLP
  • USA
  • June 6 2018

Connecticut and Maine recently joined the increasing number of states to enact drug price transparency laws. Maine’s drug price transparency law (the

HHS Releases RFI to Request Input on Drug Pricing Proposals Read more:
  • Holland & Knight LLP
  • USA
  • May 29 2018

On May 14, 2018, HHS issued a request for information (RFI) on the administration's "American Patients First" drug pricing policy blueprint. The RFI

A Look Inside Trump's 4-Point Plan For Curbing Drug Prices
  • Ropes & Gray LLP
  • USA
  • May 18 2018

On May 11, President Donald Trump outlined his administration’s four-point plan for curbing prescription drug prices. With rare exceptions, the plan

ITC Institutes Investigation Based on Allegation of Drug Sales Without FDA Approval
  • Jones Day
  • USA
  • May 17 2018

Normally, it is the FDA that monitors the improper distribution of drugs. But, as it turns out, the International Trade Commission ("ITC") might be

FDA Publishes List of Drug Companies Accused of Hindering Generic Entry: Antitrust Implications
  • Wilmer Cutler Pickering Hale and Dorr LLP
  • USA
  • May 17 2018

Today, as part of the Trump Administration's stated goal to lower drug prices, the Food and Drug Administration (FDA) published a list of

Capitol Hill Healthcare Update
  • Baker & Hostetler LLP
  • USA
  • May 14 2018

On Capitol Hill, reaction to President Donald Trump’s “American Patients First” plan to bring down prescription drug prices fell predictably along

Administration Releases Long-Awaited Drug Pricing Reform Plan
  • Cooley LLP
  • USA
  • May 11 2018

Today, the President and Health and Human Services (HHS) Secretary Alex Azar unveiled a 44-page Blueprint to Lower Drug Prices and Reduce

President set to outline drug pricing plan: how far will it go?
  • Cooley LLP
  • USA
  • May 10 2018

Tomorrow at 2 p.m., EST, the President is scheduled to deliver a long-awaited drug pricing strategy speech to put “America’s patients first.” While

Jurisdiction for “Late Listed” Orange Book Patent and Injunction Based on Induced Infringement by Drug Label
  • Oblon
  • USA
  • April 25 2018

As reported earlier, the Federal Circuit in Vanda Pharm. Inc. v. West-Ward Pharm. Int’l. Ltd. held that jurisdiction exists under 35 U.S.C